SABCS 2021

Metformin is not an anti-cancer drug

Critical consideration of the study data is necessary

Molecular-guided treatment is of value in combination…

Negative results with hope for translational projects

Hypothesis-generating study in the HER2-enriched…

Benefit only related to chemotherapy?!

Genomic signatures of DCIS

Solved and unsolved controversies of early breast…

Leading the way for other ct-DNA trials

The next standard for TNBC?!

Metformin shows no efficacy for most cancer patients

The risk-adapted decision for or against AI has to be…

Re-evaluation confirms old data

Kritische Betrachtung der Studiendaten notwendig

Negative Ergebnisse, aber Hoffnung für translationale…

E’ solo effetto della chemioterapia?

"Signatures Genomiche " nel carcinoma duttale in situ

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Hypothesen-generierende Studie beim HER2-enriched…

Erneute Auswertung bestätigt alte Daten

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

RxPONDER: Benefit only for pre-menopausal patients?…

HER2+ EBC: Chemotherapy free regimens? Extended…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

TNBC EBC: What is the new neoadjuvant standard…

More good news for TDXd

Which patients will benefit from Pembro in metastatic…

Effectiveness depending on PDL1 status

IO + IO without resounding success in the mBC setting

Immuntherapy for high tumor mutation burden in…

Pioneering study of personalized medicine in advanced…

Imaging with mass cytometry can provide predictive…

Exciting novel therapies for metastatic TNBC

Precision oncology is beneficial in certain mBC…

Pooled analyses shows OS benefit for most subgroups

Elacestrant - less than we expected

Amazing period for patients with refractory metastatic…

T-Dxd is also active in patients with brain metastasis

Activity of T-Dxd across all Her2-expressing breast…

Dato-DXd new promising ADC

Chekpoint inhibition in breast cancer

Promising results for TNBC patients

Oral SERDs are efficient, but show high progression…

Final results of the CPS score subgroup analyses show…

My highlights of 2021 in metastatic breast cancer

Robust benefit of pembroluzimab in addition to…

Dato-Dxd for metastatic TNBC

Very good news for endocrine resistant metastatic…

Samuraciclib - new targeted therapy for luminal breast…

Reconfirming effect of T-DXd in patients with brain…

3 updates - 3 new standards of care

TROP2 - new target for improved chemotherapy

PFS improvement with fulvestrant in patients with…

TDXd is very efficient in patients with brain…

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Oral SERDs for early setting and adjuvant therapy

Switching with molecular progress improves PFS

L’imaging mass cytometry può aiutare a predire…

Amélioration de la survie sans progression par le…

Activité du T-DXd dans les metastases cérébrales

Samuracyklib – nowe leczenie celowane w rakach…

Resultados finales de los análisis de los subgrupos de…

Buone notizie per i tumori mammari endocrino resistenti

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Neues Target für optimierte Chemotherapie

Wegweisende Daten für die personalisierte Medizin beim…

IO + IO ohne durchschlagenden Erfolg beim mBC

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Umstellung bei molekularem Progress verlängert PFS

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Best of the Year: Systemtherapie

Gepoolte Analyse zeigt OS Vorteil für fast alle…

T-Dxd aktywny również w przerzutach do mózgu

Risultati promettenti nel tumore al seno triplo…

Checkpoint-Inhibition beim Mammakarzinom

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Werden orale SERDs die Therapie mit Fulvestrant in…

Résultats prometteurs dans le cancer du sein triple…

Mi retrospectiva del cáncer de mama metastático en 2021

È un grande momento per i pazienti con tumore mammario…

Important benefice de l’ajout du pembrolizumab à la…

Elacestrant – poniżej oczekiwań

MBC HR+: What is the best option after a CDK4/6i…

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

Treatment options for patients with metastatic TNBC

New ADCs on the horizon for TNBC patients

Are SERDs a future therapy for endocrine resistant…

Targeting rare mutations in breast cancer - is this the…